Costo-efectividad de furoato de mometasona tópica nasal para el tratamiento de la rinosinusitis aguda en México

Universidad Industrial de Santander. Revista. Salud

Pierre K, Alexandre¹  Rely, Kely²  Salinas E, Guillermo³  Martínez V, Silvia³  Pérez B, Carlos⁵  Blandón, Virginia⁶ 

[1] Dohme de México, Ciudad de México, México;CEAHT, Ciudad de México, México;Hospital Infantil de México Federico Gómez, Ciudad de México, México;Johns Hopkins University, USA;Merck Sharp &amp

关键词: acute rhinosinusitis;    rhinosinusitis;    mometasone furoate;    cost-effectiveness;    treatment;    Mexico..;   

DOI  :  10.18273/revsal.v49n2-2017007

学科分类：医学（综合）

来源: Universidad Industrial de Santander

【 摘 要 】

Introduction: Acute rhinosinusitis (RSA) is a common cause of consultation on first level of attention and it can be solved without antibiotics use. Objective: Analysis of cost effectiveness of nasal spray mometasone furoate (NSMF) compared to amoxicillin in treatment of acute rhinosinusitis in Mexico from a National Mexican Health System perspective. Methods: Cost-effectiveness analysis comparing NSMF 200µg twice daily and amoxicillin 500mg three time daily. The effectiveness outcomes of the study were modeled as changes in the Major Symptom Score (MSS). MSS consists of five questions concerning rhinorrhea, post-nasal drip, nasal congestion, sinus headache, and facial pain. Clinical data were obtained from a randomized clinical trial. Cost were expressed in Mexican pesos 2016. Sensitivity analysis was conducted univariable and multivariable for some model parameters. Results: The projected costs were $3,261 pesos with NSMF and $3,438 pesos with amoxicillin. NSMF was associated with a cost savings per patient of $177 pesos versus amoxicillin over a 2 weeks period. The incremental cost-effectiveness ratio for NSMF dominated amoxicillin. The sensitivity analysis confirms overall cost savings and superiority in terms of effectiveness. Conclusion: In patients with non-complicated acute rhinosinusitis NSMF 200 µg twice daily produce significantly an improvement in symptoms compared to amoxicillin in patients without bacterial infections and is a cost-effective alternative for the National Health Mexican System. Editorial comment at the end of this article.

【 授权许可】

Unknown